Novartis’ Gilenya hits targets in paediatric MS trial

5th September 2017 Uncategorised 0

Novartis has released top-line data showing that Gilenya significantly reduced relapses in children and adolescents with multiple sclerosis.

More: Novartis’ Gilenya hits targets in paediatric MS trial
Source: News